LMNL(Delisted)
Liminal BioSciences·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LMNL
Liminal Biosciences Inc.
A clinical stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases
440 Armand-Frappier Boulevard, Suite 300, Laval, Quebec, H7V 4B4
--
Liminal BioSciences Inc. was incorporated on October 14, 1994 under the Canadian Business Companies Act. The company is a developmental biopharmaceutical company focused on discovering and developing new and unique small molecule therapies that regulate the G protein-coupled receptor, or GPCR pathway. The company is designing proprietary novel small molecule therapeutic candidates with the goal of developing best/first-in-class therapies for the treatment of metabolic, inflammatory and fibrotic diseases with significant unmet medical needs, using a comprehensive drug discovery platform, medicinal chemistry expertise and deep understanding of GPCR biology.
Company Financials
EPS
LMNL has released its 2023 Q2 earnings. EPS was reported at -2.15, versus the expected 0, missing expectations. The chart below visualizes how LMNL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LMNL has released its 2023 Q2 earnings report, with revenue of 84.64K, reflecting a YoY change of -30.61%, and net profit of -6.91M, showing a YoY change of -42.84%. The Sankey diagram below clearly presents LMNL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
